We studied the effects of MAbR15.7, an antibody directed against the common ,8-chain (CD-18) of a family of neutrophil adherence glycoproteins, on endothelial dysfunction and myocardial injury in a model of myocardial ischemia and reperfusion in cats. Pentobarbital-anesthetized cats were subjected to 1.5 h occlusion of the left anterior descending coronary artery (LAD) and 4.5 h of reperfusion. MI + R resulted in severe myocardial injury and endothelial dysfunction, including signifi-
Introduction
Early reperfusion remains the most effective way to curtail infarct extension and improve ventricular function. However, accumulating evidence indicates that reperfusion itself may have deleterious effects on the ischemic myocardium (1) (2) (3) and that neutrophils play a critical role in reperfusion injury (4, 5) . It has been demonstrated that either depletion of neutrophils before coronary occlusion or pharmacologically suppressing neutrophil activation exerts a significant protective effect on ischemia-reperfusion induced myocardial damage (6, 7) . Furthermore, it has been demonstrated that monoclonal antibod-ies that bind to the neutrophil adhesion-promoting glycoproteins (e.g., CDl 1/CD 18) , inhibit neutrophil aggregation and adhesion on natural and artificial substrates (8) . Recently, it has been shown that anti-Mol 904, an antibody directed against one ofthe three alpha chains (i.e., CD1 lb) ofthe neutrophil adhesive glycoprotein family, has a significant cardiac protective effect in myocardial ischemia and reperfusion in canine hearts (9) , and MAbR 15.7 appears to protect when given soon after occlusion in primates subjected to myocardial ischemia (10) .
MAbR15.7, a novel IgGl monoclonal antibody directed against the common (3-chain (CD 18) of the neutrophil adherence glycoproteins is particularly effective at blocking a wide spectrum ofneutrophil adherence related events and inhibiting neutrophil localization in ischemic canine myocardium (11) , but its effect on endothelial function and myocardial injury induced by ischemia/reperfusion is unknown. Therefore, the purposes of this study were to (a) evaluate the effect of MAbR1 5.7 given shortly before reperfusion on infiltration and accumulation of neutrophils into the ischemic cat myocardium, a reproducible model of ischemia and reperfusion; and (b) investigate the effects ofMAbR15.7 on endothelial dysfunction and myocardial injury induced by myocardial ischemia followed by reperfusion.
Methods
Adult male cats (2.5-3.4 kg) were anesthetized with sodium pentobarbital (30 mg/kg, i.v.). An intratracheal cannula was inserted through a midline incision, and all cats were placed on intermittent positive-pressure ventilation (small animal respirator; Harvard Apparatus Co., Inc., Dover, MA Experimental protocol. After completing all surgical procedures, the cats were allowed to stabilize for 30 min and a baseline reading of ECG and MABP was made and an initial blood sample was drawn. MI was produced by tightening the previously placed reversible ligature around the LAD to completely occlude the vessel. Cats were then randomly assigned to each group. This was designated as time 0. After 1.5 h of ischemia, the LAD ligature was untied and the ischemic myocardium was reperfused for 4.5 h, resulting in a total postocclusion period of 6 h. 10 min before reperfusion, the monoclonal antibody directed against CD18 (MAbR15.7) (Boehringer-Ingelheim, Ridgefield, CT) or a nonbinding control antibody ofthe IgG1 group (MAbR3. 1) was given intravenously as a bolus. Animals were randomly divided into two groups: (a) MI + MAbR3. 1 (n = 6); (b) MI + MAbR15.7, 1 mg/kg (n = 7). A dose of 1 mg/kg ofMAbR15.7 was selected because this dose was found to be in excess ofthat necessary to exert a 100% block ofCD-18 at 5-6 h in primates. Additionally, preliminary studies showed that 0.5 mg/kg of MAbR15.7 was only partially effective in protecting the ischemic myocardium. Moreover, flow cytometry of isolated neutrophils show cross-reactivity ofMAbR 15.7, but not MAbR3. 1, with cat neutrophils at comparable doses to that of primates.
Plasma creatine kinase analysis. Arterial blood samples (2 ml) were drawn immediately before ligation and hourly thereafter. The blood was collected in polyethylene tubes containing 200 IU of heparin sodium. Samples were centrifuged at 2,000 g and 40C for 20 min and plasma was removed for biochemical analysis. Plasma protein concentration was assayed using the biuret method ( 12) . Plasma creatine kinase (CK) activity was measured in a blind manner using the method of Rosalki (13) and expressed as IU per milligram of protein.
Myocardial tissue analysis. At the end of the 6 h experimental period, the ligature around the LAD was retightened. Then, 30 ml of 0.5% Evans blue was injected into the left atrium to stain that area of myocardium that was perfused by the patent coronary arteries. The area-at-risk was thus determined by negative staining. The heart was rapidly excised and placed in warmed, oxygenated Krebs-Henseleit solution. The left circumflex (LCX) and the LAD coronary arteries were isolated and removed for the subsequent study ofcoronary ring vasoactivity. Then the right ventricle and great vessels were removed and the left ventricle was sliced parallel to the atrioventricular groove in 3-mm thick sections. The unstained portion ofthe myocardium (i.e., the total area-at-risk) was separated from the Evans blue stained portion of the myocardium (i.e., the area-not-at-risk). The area-at-risk was again sectioned into 1-mm thick slices and incubated in 0.1% nitroblue tetrazolium in phosphate buffer at pH 7.4 and 370C for 15 min. The tetrazolium dye forms a blue formazan complex in the presence ofcoenzymes and dehydrogenases. The irreversibly injured or necrotic portion ofthe myocardium at risk which did not stain was separated from the stained portion of the myocardium (i.e., the ischemic but non-necrotic area). All three portions of the left ventricular myocardium (i.e., non-ischemic, ischemic non-necrotic, and ischemic necrotic) were Isolated coronary ring studies. Both LAD and LCX coronary segments removed were placed into warmed K-H buffer consisting of(in mM): NaCl, 118; KC1, 4.75; CaCl2-2H20, 2.54; KH2PO4, 1.19; MgSO4. 7H20, 1.19; NaHCO3, 12.5; and glucose, 10.0. Isolated coronary vessels were cleaned and cut into rings of 2 to 3 mm in length. The rings were then mounted on stainless steel hooks, suspended in 10-ml tissue baths, and subsequently connected to FT-03 force displacement transducers (Grass Instrument Co.) to record changes in force on a Grass model 7 oscillographic recorder. The baths were filled with 20 ml of K-H buffer and aerated at 370C with agas mixture of 95%°2 and 5% CO2. Coronary rings were initially stretched to give a preload of 0.5 g of force and equilibrated for 60-90 min. During this period, the K-H buffer in the tissue baths was replaced every 20 min. After equilibration, the rings were then exposed to 10 ng/ml U-46619 (Upjohn Co., Kalamazoo, MI), a thromboxane A2 mimetic, to generate 0.5 g of developed force. Once a stable contraction was obtained, 0.1, 1, 10, and 100 nM acetylcholine (ACh) was added to the bath. After the response stabilized, the rings were washed and allowed to equilibrate to baseline once again. The procedure was repeated with A-23187 (1, 10, 100, and 1000 nM) and then to NaNO2 (0.1, 1, 10, and 100 MM). NaNO2 was prepared by dissolving the compound in 0.1 N HCQ and titrating it to pH 2.0. Titrating distilled water to pH 2.0 and adding aliquots to buffer in the bath did not produce any vasorelaxation.
In neutrophil adherence studies, opened cat coronary rings were placed in 5 ml of K-H buffer, and 100 nM f-methionyl-leucyl-phenylalanine and 400,000 labeled neutrophils/ml were added. Coronary rings were removed 20 min later for fluorescence microscopy, and the numbers of neutrophils adhering to the endothelial surface was counted and averaged per 100x magnification field.
Determination oftissue myeloperoxidase. The myocardial activity of myeloperoxidase (MPO), an enzyme occurring virtually exclusively in neutrophils, was determined using the method of Bradley et al. (14) as modified by Mullane et al. (15) . The myocardium was homogenized in 0.5% hexadecyltrimethyl ammonium bromide (HTAB) (Sigma Chemical Co., St. Louis, MO) and dissolved in 50 mM potassium phosphate buffer (pH 6) using a Polytron (PCU-2) homogenizer (Kinemutica GmbH, Luzern, Switzerland). Homogenates were centrifuged at 12,500 g, 2°C for 30 min. The supernatants were then collected and reacted with 0.167 mg/ml of o-dianisidine dihydrochloride (Sigma Chemical Co.) and 0.0005% H202 in 50 mM phosphate buffer at pH 6.0. The change in absorbance was measured spectrophotometrically at 460 nm. 1 U ofMPO is defined as that quantity ofenzyme hydrolyzing 1 gmol of peroxide/min at 25°C.
Labeling of neutrophils. Autologous cat neutrophils were labeled using the Zynaxis PKH2 dye (Zynaxis Cell Science, Inc., Malvern, PA) based on the procedure of Yuan and Fleming (16). 1 ml of diluent was added to a loose cell pellet containing < 10,000,000 cells. 1 ml of PKH2-GL dye (4 uM) was then added to the cell suspension and then mixed for 5 min by inversion. 2 ml of PBS (containing 10% plateletpoor plasma in PBS) was added to stop the reaction and another 5 ml of PBS was underlayered in the suspension. Cells were then centrifuged at 400 g for 10 min at room temperature. Supernatant was removed and the cells were resuspended in PBS and then recounted. Labeling procedure yields cells possessing normal morphology and function (17) .
Statistical analysis. All values in the text, table, and figures are presented as means±standard error of the means of n independent experiments. All data were subjected to ANOVA followed by the Bonferroni correction for post-hoc t test. Probabilities of 0.05 or less were considered to be statistically significant.
Results
In preliminary studies, we observed that administration of MAbR1 5.7 intravenously at a dose of 1 mg/kg had no effect on any of the hemodynamic or electrocardiographic variables observed in nonischemic control cats. There were no significant differences in any of the variables observed initially between the two MI groups ofcats. Table I summarizes the ST-segment elevation and the PRI in the two MI groups. Within a few minutes of LAD occlusion, the ST-segment became elevated and peaked at 20-40 min after coronary occlusion. At reperfusion, the ST-segment decreased to close to control values. All cats subjected to MI exhibited a comparable increase in ST-segment elevation, indicating that the ischemic insult was similar between the two MI groups. Immediately after coronary occlusion, PRI decreased, resulting in a significant decrease in myocardial oxygen demand. Thereafter, the PRI increased gradually and returned to the preocclusion level at the end of the experiment. There were no significant differences between groups at any of the hourly readings. This lack of a significant difference in PRI between groups suggests that administration of MAbR1 5.7 has no significant effect on myocardial oxygen demand during myocardial ischemia and reperfusion. At reperfusion, there was a noticeable increase in the incidence of premature ventricular contractions (PVCs). One cat in each group developed ventricular fibrillation which was resistant to cardioversion, and were thus excluded from further study. There was no overall difference between MI groups in the number of PVCs occurring postreperfusion, indicating that MAbR15.7 does not appear to exert any major anti-arrhythmic effect.
Plasma CK activity was measured hourly during the course of the 6-h experimental period. A significant washout of CK into circulating blood occurred 30 min after reperfusion in MI cats receiving only the control antibody. These elevated plasma CK activities remained higher for the remaining 4 h. In contrast, MI cats treated with MAbR1 5.7 developed significantly lower plasma CK activities compared with MI cats treated with the control antibody at every time point after reperfusion (see Fig. 1 ). This was not due to a direct effect ofMAbR15.7 on the CK assay, as addition of MAbR1 5.7 directly to cat plasma did not affect the CK assay results (i.e., duplicate values with and without exogenously added MAbRl 5.7 were within 5% ofeach other). Thus, four plasma samples drawn from untreated MI cats at 6 h were 47±5 IU/mg protein X 10-3 vs. 45±4 IU/mg protein x IO-' in these same samples reassayed in the presence of 20 ,g/ml of MAbR 15.7.
To verify plasma CK activity as an index ofpreservation of ischemic tissue, and to ascertain the effects of MAbR15.7 on the degree of myocardial salvage of ischemic or necrotic tissue after reperfusion, we also measured the area-at-risk ofthe ischemic heart and the amount ofnecrotic cardiac tissue expressed as a percentage of either the area-at-risk or of the total left ventricular mass (Fig. 2) . There is no significant difference in area-at-risk expressed as percentage of total left ventricle between groups, indicating a comparable initial ischemic insult existed. However, the necrotic area either expressed as percentage of area-at-risk or of total left ventricular mass was significantly lower in cats treated with MAbRl 5.7 than that observed in cats receiving the control antibody. Thus, administration of MAbR1 5.7 significantly prevented myocardial damage induced by ischemia and reperfusion.
Infiltration of the ischemic region by neutrophils during reperfusion has been thought to be one of the major mechanisms responsible for reperfusion injury. We measured MPO activity of the three different portions of the myocardium as a marker for neutrophil adherence. These results are summarized in Fig. 3 . It is evident that in the nonischemic myocardium (i.e., area-not-at-risk), MPO activity was very low in both MI groups and there was no significant difference between them, indicating that there was no significant infiltration of neutrophils in the nonischemic myocardium. However, MI cats receiving the control antibody exhibited a marked increase in MPO activity in the ischemic region, with a 10-to 12-fold increase in MPO activity in the necrotic myocardium. In contrast, MAbRl 5.7-treated ischemic cats showed a significant decrease in MPO activity, both in ischemic-nonnecrotic and in necrotic myocardial tissue. This result indicates that adherence and infiltration of neutrophils to ischemic myocardium was significantly inhibited by MAbR15.7 .
Because endothelial cells exert a very important role in ischemia and reperfusion injury, we also tested endothelial integrity as measured by vasoactivity of coronary artery rings to the endothelium-dependent vasodilators, ACh, and A-23 187, and to the endothelium-independent vasodilator, NaNO2. Fig. 4 illustrates a typical recording of ischemic LAD coronary rings obtained from cats either receiving MAbR3. 1 for six to seven cats. ne (Hours) Plasma CK activity rises slightly after ischemia and increases significantly after reperfusion in cats given MAbR3. 1, but only slight increases occur in MI cats given MAbR15.7, a monoclonal antibody directed against CD-18. MI + MAbR 3.1 (-o-). MI + MAb R15.7 (-* -).
lator, NaNO2. Fig. 5 summarizes the statistical evaluation of the vasorelaxant response to ACh, A-23187, and NaNO2 in isolated cat LAD coronary artery rings. Clearly, the response of ischemic LAD coronary rings to the endothelium-dependent vasodilators was significantly preserved in the MAbRl5.7-treated cats. Fig. 6 illustrates the vasorelaxant response of paired LCX coronary rings studied as a control. The nonischemic LCX rings, whether obtained from untreated group or antibody-treated ischemic cats showed equally well and complete relaxant response to ACh, A-23187, and NaNO2. There were no significant differences in response to any ofthe vasodilators studied between the two groups of LCX coronary artery rings.
To test whether MAbR1 5.7 has any direct effect on coronary artery tone, additional experiments were done using the LAD coronary artery rings from control nonischemic cats. followed by 5 h of reperfusion in dogs (15) . Additional support for the concept of neutrophil-mediated myocardial injury has been obtained in neutropenic or neutrophil blocked animals during myocardial ischemia and reperfusion (6) . Other experiments show that inhibitors of 5-lipoxygenase metabolism (19) , prostacyclin, or its analogues (20, 21) , or agents that inhibit the activation of neutrophils (21) are also effective in reducing experimental myocardial injury during reperfusion by reducing the extent of neutrophil accumulation within the previously ischemic myocardium. It is proposed that neutrophil adherence to endothelial cells is a prerequisite for deleterious effects of these leukocytes on endothelium and myocardium (22, 23) . Immunological studies have demonstrated that a family ofheterodimeric glycoproteins possessing a common 13-chain (CD-18) and one of three separate a-chains (i.e., CD1 la, CD1 lb, or CD1 lc) are expressed on the surface of the neutrophils (24) . It has been well recognized that the CD1 1/CD-18 glycoprotein family plays a critical role in neutrophil adherence (25) . Antibodies either directed against the common ,8-chain, CD-18 (MAb 60.3) (26, 27) , MAb IB4 (28), or against separate a-chains, CDl la (TSl/ 22) (29) and CDl lb (MAb 60.1) (30) significantly inhibit the adherence of neutrophils to the endothelium by an effect on neutrophils rather than direct effects on their endothelial ligands. However, it has recently been proposed that the relative importance of the three separate a-chains in the adherence of neutrophils to endothelium varies and is dependent on "activation states" of both the neutrophils and the endothelial cells. Arnaout et al. (31) have demonstrated that PMA-induced adhesion of granulocytes to endothelial cells was mediated primarily by CD-l lb/CD-1 8. Moreover, this process was not inhibited by monoclonal antibodies against CD-1 la/CD-1 8 or CD-l lc/CD-18. On the other hand, Smith et al. (32) have shown that unstimulated neutrophils adhere to human umbilical vein endothelium in vitro via CD-1 la/CD-1 8-dependent attachment to intercellular adhesion molecule-l (ICAM-l), whereas neutrophils stimulated with chemoattractant adhere to these endothelial cells via a CD-1 lb/CD-1 8-dependent at- Figure 6 . Summary of responses of nonischemic LCX coronary rings to 100 nM ACh, 1 IAM A-23187, and 100,uM NaNO2. Bar tachment mechanism via ICAM-1 receptors. Because a variety of "activation states" ofthe neutrophils and endothelium may occur at different times during myocardial ischemia and reperfusion, the antibody that is specifically directed to one of the a-chains of the CD-l 1 family of glycoproteins may not fully inhibit neutrophil adherence. Additional studies on endotheHal function in coronary veins would also be a fruitful area of investigation because venous endothelium is thought to be a more critical site ofneutrophil adherence than the arterial endothelium.
Our results clearly show that administration ofan antibody to the common 13-chain of the adhesive glycoprotein family (i.e., CD-18) before reperfusion has significant protective effects on endothelial dysfunction and myocardial injury induced by myocardial ischemia and reperfusion. Interestingly, compared with other results obtained from employing an antibody directed against one ofthe a-chains, Anti-Mol 90410 or its F(ab')2 fragments (33) on myocardial reperfusion injury in a dog model, we have observed a greater suppression of neutrophil accumulation in ischemic myocardium and a greater cardioprotective effect with an antibody directed against common 13-chain in a cat ischemia/reperfusion model. Whether this reflects a difference in the efficacies of the antibodies or whether it represents differences between cat or dog ischemia models remains to be tested. In this regard, MAbR15.7 exerted the most striking anti-ischemic event of any agent we have ever studied in our model ofreperfusion injury. Although it appears that MAbR1 5.7 protects against the cardiac injury due to both the direct ischemic as well as the reperfusion phases of the myocardial ischemia-reperfusion protocol, this is not entirely the case. In this cat model of ischemia-reperfusion, Tsao et al. (34) have shown that 90 min of permanent occlusion results in a percentage of necrosis/AAR of only 1.2±0.9%. This only increases to 6.9±2.2% at 4.5 h (35) . Thus, in the cat model of LAD occlusion, the early injury due to direct ischemia is not great. It requires longer times to develop significant injury. At 24 h, significant injury to the left ventricle occurs (i.e., 20% of the left ventricle or 75% ofthe area-at-risk) (36) . Recently, Welbourn et al. (37) using MAbR 15.7 in hindlimb ischemia and reperfusion in rabbits, found that this antibody reduced neutrophil diapedesis into dermabrasion chambers by over 99%, and was much more effective than a leukotriene B4 receptor antagonist in this regard. These findings help explain the remarkably effective results in curtailing myocardial injury in our experi- 
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of the antibody on preserving endothelial function in vivo which could, if they occur, contribute to the anti-ischemic effect. The endothelial-preserving effect of MAbR1 5.7 in our experiments presumably occurs within the first 20 min after reperfusion when 65 to 75% of the endothelial dysfunction occurs (34) . This is before significant infiltration of neutrophils into the ischemic area (34) . Our findings can be explained by either (a) a direct endothelial protective effect ofMAbR 15.7, or (b) a protective effect of this antibody on neutrophils preventing their activation and release of cytotoxic mediators after reperfusion. Among these mediators, free radicals are generally considered to be the most significant cytotoxic products derived from activation of neutrophils (38) . In this connection, superoxide ions have been shown to inactivate EDRF (39), initiate lipid peroxidation, and alter membrane permeability to ions, all of which can lead to significant endothelial dysfunction. In addition, TNF significantly inhibits EDRF release from cat carotid and coronary arteries stimulated by ACh (40). Although we cannot explicitly differentiate between these two possibilities, inhibition of the release of mediators from the activated neutrophil is probably the more likely mechanism of endothelial protection by MAbR1 5.7.
Several possibilities may explain the protective mechanism ofantibody MAbRl 5.7 on myocardial cell injury which occurs along with neutrophil accumulation at 3 h after reperfusion in this model of ischemia and reperfusion (34) . First, it is well recognized that neutrophils release a variety of mediators that directly promote myocardial tissue injury, including proteolytic enzymes, platelet activating factor, arachidonic acid metabolites, and oxygen-derived free radicals (4). Because neutrophil activation is a prerequisite for the release ofthese cytotoxic products, MAbR1 5.7 may exert its cardioprotective effect by inhibiting the neutrophil adherence to endothelium and subsequent diapedesis into the myocardium, thereby reducing the release of deleterious mediators of neutrophil origin into the environment of ischemic myocardial cells. In this connection, we have previously shown that cat neutrophils in the presence off-MLP induce coronary vasoconstriction and retard endothelium-dependent vasorelaxation in coronary artery rings isolated from cats subjected to myocardial ischemia and reperfusion (41 
